Global Hormone Replacement Therapy Market
The Global Hormone Replacement Therapy Market, by Route of Administration (Parenteral and Oral), by Therapy Type (Testosterone Replacement Therapy, Thyroid Replacement Therapy, Estrogen Replacement Therapy, and HGH (Human Growth Hormone) Replacement Therapy), by Application (Menopause, Hypothyroidism, Growth Hormone Deficiency, and Male Hypogonadism), by Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and by Region (North America, Asia Pacific, Europe, Latin America, Middle East, and Africa) had a market valuation of US$ 10.58 Billion in 2017, and is estimated to grow at a CAGR of 5.2 percent during the forecast period (2018 – 2026).
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2079
The global hormone replacement therapy market is growing due to substantial studies in the areas of nephrology that are generating therapies and novel medicines for the treatment of hyperparathyroidism. Sanofi SA’s Hectorol capsules are now undertaking Phase 3 clinical studies to assess the medication’s safety and effectiveness in decreasing secondary hyperparathyroidism in juvenile patients with chronic kidney disorders. The drug’s clinical trials are scheduled to be finished in December 2017, after which it will be commercially accessible. The expansion of the global hormone replacement therapy market is likely to be boosted by increased partnerships among major players to accelerate the development of medicines for hormone replacement. Shire plc. and NanoMedSyn, a French biotech firm, announced a preclinical research cooperation in March 2018 to create an enzymatic replacement therapy for a lysosomal storage disease based on NanoMedSyn’s synthetic derivative technology called AMFA.
Browse 23 Market Data Tables and 19 Figures spread through 151 Pages and in-depth TOC on “Global Hormone Replacement Therapy Market, by Route of Administration (Parenteral and Oral), by Therapy Type (Testosterone Replacement Therapy, Thyroid Replacement Therapy, Estrogen Replacement Therapy, and HGH (Human Growth Hormone) Replacement Therapy), by Application (Menopause, Hypothyroidism, Growth Hormone Deficiency, and Male Hypogonadism), by Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and by Region (North America, Asia Pacific, Europe, Latin America, Middle East, and Africa) – Global Forecast to 2026”
Companies in the global hormone replacement therapy market are focusing on expanding their product portfolio by launching generic products on a regular basis, particularly in the U.S. In January 2018, Teva Pharmaceutical Industries Ltd. launched an authorized generic version of Estrace1 Cream in the U.S. for the treatment of moderate to severe vulvar and vaginal atrophy caused by menopause. This launch is a significant addition to Teva’s generic women’s health portfolio and increasing range of menopausal therapies, which are projected to drive the global hormone replacement therapy market forward during the forecast period. Furthermore, the market is anticipated to increase due to the rising usage of hormone replacement therapy in various nations. Abbott Laboratories received regulatory clearance for oral dydrogesterone medication in Russia and the Netherlands in August 2017. Dydrogesterone, which has been used to treat diseases associated with progesterone deficiency for over 50 years, has recently been authorized as a therapeutic option for uterine preparation in women undergoing IVF (in vitro fertilization) treatment in these nations.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/2079
The global hormone replacement therapy market is anticipated to grow at a CAGR of 5.2 percent from 2018 to 2026, owing to an increase in hormonal diseases that need the use of such treatments.
The estrogen hormone replacement treatment sector has the largest market share among therapy types, owing to the FDA’s approval of several hormone agents for use in MHT (menopausal hormone therapy). Premarin, Menest, and Combipatch are among the most profitable drugs on the market. As per Pfizer’s statistics, Premarin sold 1,076 million on its own in 2014.
Key companies contributing in the global hormone replacement therapy market are Pfizer Inc., QuatRx Pharmaceuticals, Mylan N.V., Abbott Laboratories, Amgen, Inc., Novartis AG, Eli Lilly and Company, Bayer AG, Merck KgaA, Teva Pharmaceutical Industries Ltd., and Novo Nordisk A/S.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027